Abstract | BACKGROUND: OBJECTIVE: To compare the influence of pimecrolimus cream 1% on different standard eczema scores in infants with atopic dermatitis and to analyse the impact of treatment on the individual morphological key signs of eczema. METHODS:
Pimecrolimus cream 1% (n = 129) or double-blind vehicle control (n = 66) was administered for 4 weeks. The Eczema Area and Severity Index (EASI), Investigators' Global Assessment ( IGA) and Scoring Atopic Dermatitis Index (SCORAD) were determined and were correlated with each other. RESULTS: Following treatment with pimecrolimus, the EASI, IGA and SCORAD were significantly reduced on day 29 as compared with the vehicle group (p < 0.001, p < 0.001, p = 0.002, respectively). There was a close correlation between EASI, IGA and SCORAD. The single parameters of the EASI were already significantly decreased by day 4 in the pimecrolimus group as compared to vehicle (each p < 0.001). CONCLUSION: Treatment with pimecrolimus 1% cream leads to a rapid improvement of all morphological signs of eczema. The close correlation of different scores was shown for the first time.
|
Authors | Kristine Breuer, Matthias Braeutigam, Alexander Kapp, Thomas Werfel |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 209
Issue 4
Pg. 314-20
( 2004)
ISSN: 1018-8665 [Print] Switzerland |
PMID | 15539895
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright (c) 2004 S. Karger AG, Basel. |
Chemical References |
- Ointments
- pimecrolimus
- Tacrolimus
|
Topics |
- Administration, Topical
- Biopsy, Needle
- Dermatitis, Atopic
(complications, drug therapy, pathology)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Eczema
(complications, drug therapy, pathology)
- Female
- Follow-Up Studies
- Humans
- Immunohistochemistry
- Infant
- Male
- Ointments
- Probability
- Reference Values
- Risk Assessment
- Severity of Illness Index
- Tacrolimus
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|